

SUPPLEMENTARY DATA

Quantitative Analysis of TALE-DNA Interactions Suggests Polarity Effects

Joshua F. Meckler^{1†}, Mital S. Bhakta^{1†}, Moon-Soo Kim^{1§}, Robert Ovadia², Chris H. Habrian²,
Artem Zykovich¹, Abigail Yu¹, Sarah H. Lockwood¹, Robert Morbitzer³, Janett Elsässer³,
Thomas Lahaye³, David J. Segal^{1*} and Enoch P. Baldwin^{2*}

¹Genome Center and Department of Biochemistry and Molecular Medicine, ²Department of Molecular and Cellular Biology, University of California, Davis, CA 95616, ³Department of Biology, Institute of Genetics, Ludwig-Maximilians-University Munich, 82152 Martinsried, Germany

[§]Current address: Department of Chemistry, 1906 College Heights Blvd., Western Kentucky University, Bowling Green, KY 42101.

[†]These authors contributed equally to this work

*Address correspondence to: djsegal@ucdavis.edu and epbaldwin@ucdavis.edu

Table of Contents

Figure S1: Sequences of dTALEs used in this study.	3
A) N- and C-terminal truncations reported by several studies.	3
B) Construct sequences for bacterial expression for <i>in vitro</i> assays.....	4
C) Construct sequences for eukaryotic expression for reporter assays.....	9
Figure S2: Coomassie-stained protein gel of representative dTALEs.	11
Figure S3. Representative EMSA data.	12
Figure S4: Correlation of affinity with reporter gene activation.	13
Table S1: Primers used to create N- and C-terminal truncations.....	14
Table S2: Primers used in EMSA assays.	15
Table S3: Primers for construction of ATF reporter plasmids.	16
Table S4: EMSA and ATF data for G/A specificity of the NN RVD.	19
Table S5: EMSA and ATF data probing the requirement of a 5'T.	19
Table S6: EMSA and ATF data for polarity effects.	20
References.....	21

Figure S1: Sequences of dTALEs used in this study.

A) N- and C-terminal truncations reported by several studies.

this study

Mussolino et al. (1)

Sun et al. (3)

Zhang et al. (5)

Miller et al. (2)

PthXo1 structure (4)

dHax3 structure (6)

BamHI

254-this study

| 287-Mussolino et al, Sun et al

||

MDPI

RPRRPSPARELLPGPQPDRVQPTADRGVSAPAGSPLDGLPARRTVSRTRL 201

207 Sun et al

PSPPAPSPAFSAGSFSDLLRPFDPSSLDTSSLDSMPAVGTPHTAAAPAEW 151

N2-Zhang et al

Factor Xa

111-this study

153-Mussolino et al

Δ152-Miller et al

| 135-Sun et al

DEAQSALRAADDPPPTVRVAVTAARPPRAKPAAPRRRAAQPSDASPAQVD 101

N3-Zhang et al

N5-Zhang et al

N6-Zhang et al

94 this study

| 125-Sun et al

N7-Zhang et al

PthXo1 Struct

N4-Zhang et al

LRTLGYSSQQQEQEKIKPKVVRSTVAQHHEALVGHGFTHAHIVALSQHPAALG 051

dHax3 Struct

N8-Zhang et al

| 50-Sun et al

| 49-Mussolino et al

TVAVTYQHIITALPEATHEDIVGVGKQWSGARALEALLTDAGELRGPPLQ 001

LDTGQ...

--- TALE REPEATS ---

...SRPDP

+28-Miller et al 47-Mussolino et al

| 31-Sun et al

| Factor Xa

| C4-Zhang et al

42 this study

| Factor Xa

| Factor Xa

| 17-Mussolino et al

ALAAL^TNDHLVALACL^GGR^PAMDAV^KKGLPHAP^ELIR^RVNR^RRIGERTSHR 050

+63-Miller et al, Sun et al

| C3-Zhang et al

VADYAQVVRVLEFFQCHSHPAYAFDEAMTQFGMSRNLVQLFRRVGVTEL 100

117-Sun et al

EARGGTLPPASQRWDRILQASGMKRAKPSPTSAQTPDQASLHAFADSLER 150

163-Sun et al (imprecise due to low conservation with AvrXa10)

180 this study

| 200-Sun et al

DLDA^PSPMHEGD^QTRASSR^KRSRSDRAV^TGPSAQ^QAVEV^RVRPE^QRDALHL 200

BamHI

231-Mussolino et al

PLSWRVKRPRTRIWGLPDPGTPMAADLAASSTVMWEQDADPFAGAADD^F 250

PAFN^EEELAWLMELL^PQ*

B) Construct sequences for bacterial expression for *in vitro* assays

Factor Xa site: IEGR[^]

TEV protease site: ENLYFQ[^]S

XhoI: **CTCGAG**

BamHI: **GGATCC**

StuI: **AGGCCT**

AatII: **GACGTC**

AgeI: **ACCGGT**

HindIII: **AAGCTT**

His6-purification tag: HHHHHH

Construct Schema:

MBP(not shown)-Factor Xa-TEV-XhoI**BamHI**-StuI-**TALE repeats**-AatII-AgeI-His6-Stop-**HindIII**

AvrBs3₂₅₄₋₁₈₀ in pMal-TEV

ATCGAGGGAAGGCTCGAAAATCTTTATTTTCAGTCTCTCTCGAGGATCCATTTCGTTTCGCGCACACCAAGTCCTGCCCGCGAGCTTCTGCCCGGACCCCAACCCGATGGGGTTCAGCCGACTGCAGATCGTGGGGTGTCTCCGCCTGCCGGCGGCCCTGGATGGCTTGCCCGCTCGGCGGACGATGTCCCGGACCCGGCTGCCATCTCCCCCTGCCCCCTCACCTGCGTTC TCGGCGGGCAGCTTTCAGTGACCTGTTACGTACGTTTCGATCCGTCACCTTTTAAATACATCGCTTTTTGATTTCATTGCC TCCCTTCGGCGCTCACCATACAGAGGCTGCCACAGGCGAGTGGGATGAGGTGCAATCGGGTCTGCGGGCAGCCGACG CCCCCACCCACCATGCGCGTGGCTGTCACTGCCGCGCGGCCGCCGCGCCAAGCCGGCGCCGCGACGACGTGCT GCGCAACCCTCCGACGCTTTCGCCGGCCGCGCAGGTGGATCTACGCACGCTCGGCTACAGCCAGCAGCAACAGGAGAA GATCAAACCGAAGGTTTCGTTTCGACAGTGGCGCAGCACCACGAGGCACTGGTTCGGCCATGGGTTTACACACGCGCACA TCGTTGCGCTCAGCCAACACCCGGCAGCGTTAGGGACCGTTCGCTGTCAAGTATCAGGACATGATCGCAGCGTTGCCA GAGGCGACACACGAAGCGATCGTTGGCGTCGGCAAACAGTGGTCCGGCGCACGCGCTCTGGAGGCCTTGCTCACGGT GCGGGGAGAGTTGAGAGGTCCACCGTTACAGTTGGACACAGGCCAACTTCTCAAGATTGCAAAACGTGGCGGGCGTGA CCGCAGTGGAGGCAGTGCATGCATGGCGCAATGCACTGACGGGTGCCCCCTGAACCTGACCCCGGAGCAGGTGGTG GCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGTGTGTGCCAGGCCCA TGGCCTGACCCCGCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTGCAGCGGC TGTTCGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGCAGCAGGTGGTGGCCATCGCCAGCAATAGCGGTGGCAAG CAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGC CATCGCTCGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGTGTGTGCCAGGCCCATG GCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTG TTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCA GCGCTGGAGACGGTGCAGGCGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCA TCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCGGTGTGTGCCAGGCCCATGGC CTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTT GCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGG CGCTGGAGACGGTGCAGCGGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGCAGCAGGTGGTGGCCATC GCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCT GACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATAGCGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGC CGGTGTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATAGCGGTGGCAAGCAGGCG CTGGAGACGGTGCAGCGGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGC CAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGA CCCCAGGACAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCG GTGCTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCT GGAGACGGTGCAGCGGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGCAGCAGGTGGTGGCCATCGCCA GCAATGGCGGCGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACC CCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGT GCTGTGCCAGGCCCATGGCCTGACCCCGCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGCGGCAAGCAGGCGCTGG AGAGCATTGTTGCCAGTTATCTCGCCCTGATCCGGCGTTGGCCGCGTTGACCAACGACCACCTCGTCGCCTTGCC TGCCTCGGCGGACGTCCTGCGCTGGATGCAGTGAAAAGGGATTGCCGACGCGCCGGCCTTGATCAAAAAGAACCAA TCGCCGTATTCGGAACGCACATCCCATCGCGTTGCCGACCACGCGCAAGTGGTTTCGCGTGTGGGTTTTTTCCAGT GCCACTCCCACCCAGCGCAAGCATTGATGACGCCATGACGCAGTTCGGGATGAGCAGGCACGGGTTGTTACAGCTC

GCTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGG
AGACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCATGGCCTGACCCCGCAGCAGGTGGTGGCCATCGCCAGC
AATGGCGGTGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCATGGCCTGACCC
GGAGCAGGTGGTGGCCATCGCCAGCAATAGCGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCGGTG
TGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATAGCGGTGGCAAGCAGGCGCTGGAG
ACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCA
CGATGGCGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCATGGCCTGACCCCG
AGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGTGCTG
TGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGAC
GGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCATGGCCTGACCCCGCAGCAGGTGGTGGCCATCGCCAGCAATG
GCGGCGGAGGCCGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCATGGCCTGACCCCGGAG
CAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGTGCTGTG
CCAGGCCCATGGCCTGACCCCGCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGCGGAGGCCGGCGCTGGAGAGCA
TTGTTGCCAGTTATCTCGCCCTGATCCGGCGTTGGCCGCTTGACCAACGACCACCTCGTCGCCTTGGCCTGCCTC
GGCGGACGTCCTGCCATGGATGCAGTAAAAAGGGACTGCCGCACGCGCCGAATTGATCAGAAGAGTCAATCGCCG
TCCGGATCCTACCGGTCATCACCATCACCATCACTGAAGCTT

IEGRLENLYFOSLEMDPSOQQQEKIKPKVRSSTVAQHHEALVGHGFTHAHIVALSOHPAAL

GTVAVTYQHIITALPEATHEDIVGVGKQWSGARALEALLTVAGELRGPPLQ

LDTGQLLKIARKGGVTAVEAVHAWRNALTGAPLN

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

LTPEQVVAIASHDGGKQALETVQRLLPVLCQAHG

II-NGp₁₁₁₋₄₂ in pMal-TEV

ATCGAGGGAAGGCTCGAAAATCTTTATTTTCAGTCTCTCGAGATGGATCCCTCCGACGCTTCGCCGGCCGCGCAGGT
GGATCTACGCACGCTCGGCTACAGTCAGCAGCAGCAAGAGAAGATCAAACCGAAGGTGCGTTTCGACAGTGGCGCAGC
ACCACGAGGCACTGGTGGGCCATGGGTTTACACACGCGCACATCGTTGCGCTCAGCCAACACCCGGCAGCGTTAGGG
ACCGTCGCTGTACGTATCAGCACATAATCACGGCGTTGCCAGAGGCGACACACGAAGACATCGTTGGCGTCGGCAA
ACAGTGGTCCGGCGCACGCGCCCTGGAGGCTTGCTCACGGTGGCGGGAGAGTTGAGAGGTCCACCGTTACAGTTGG
ACACAGGCCAACTTCTCAAGATTGCAAAACGTGGCGGCGTGACCGCAGTGGAGGCAGTGCATGCATGGCGCAATGCA
CTGACGGGTGCCCCCTGAACCTTACGCCGAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCT
GGAGACGGTGCAGCGGCTGCTTCCGGTGCTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCA
GCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGCGATTGTTGCCGGTGCTGTGCCAGGCCCATGGCCTGACC
CCGGAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACTGTCCAGCGGCTGTTGCCGGT
GCTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTTG
AGACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGC
AATGGCGGTGGCAAGCAGGCTCTGGAGACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGCCCATGGCCTGACCC
GGAGCAGGTGGTGGCCATCGCCAGCCACGACGGGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGTG

TGTGCCAGGCCCATGGCCTGACCCCGCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGGCGCAAGCAGGCGCTGGAG
ACGGTGCAGGCGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCAAGCAA
TAAGGGTGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGG
AGCAGGTGGTGGCAATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGTGTGT
TGCCAGGCCCATGGCCTGACCCCGCAACAGGTGGTAGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGAC
GGTGCAGCGGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACACCCAGCAGGTGGTAGCGATCGCCAGCAATG
GCGGTGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGCTTCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGGAG
CAGGTGGTGGCCATCGCCAGCCACGATGGCGGCAAGCAGGCGCTGGAGACGGTGCAGCGATTGTTGCCGGTGTGTG
CCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACTG
TCCAGCGGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATGGC
GGTGGCAAGCAGGCGCTTGGAGACGGTGCAGCGGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGGAGCA
GGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCTCTGGAGACGGTGCAGCGGCTGTTGCCGGTGTGTGCC
AGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATAAGGGGGCAAGCAGGCGCTGGAGACGGT
CAGCGGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGCAGCAGGTGGTGGCCATCGCCAGCAATGGCGG
CGGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACACCCAGCAGG
TGGTGGCCATCGCCAGCAATGGCGGGCGGAGGCGGCTGGAGAGCATTGTTGCCAGTTATCTCGCCCTGATCCG
GCGTTGGCCGCTTGACCAACGACCACCTCGTCGCCTTGGCCTGCCTCGGCGGACGTCCTGCCATGGATGCAGTGAA
AAAGGGACTGCCGCACGCGCCGAATTGATCAGAAGAGTCAATCGCCGTCCGGATCCTACCGGTTCATCACCATCACC
ATCACTGAAGCTT

IEGRLENLYFQSLEMDPDSASPAAQVDLRTLGYSSQQQEKIKPKVRSSTVAQHHEALVGHG
FTHAHIVALSQHPAALGTVAVTYQHIIITALPEATHEDIVGVGKQWSGARALEALLTVAGE
LRGPPLQ

LDTGQLLKIARKGGVTAVEAVHAWRNALTGAPLN
LTPQQVVAIASNNGGKQALETVORLLPVLCQAHG
LTPEQVVAIASNIGGKQALETVORLLPVLCQAHG
LTPQQVVAIASNNGGKQALETVORLLPVLCQAHG
LTPQQVVAIASNNGGKQALETVORLLPVLCQAHG
LTPQQVVAIASNNGGKQALETVORLLPVLCQAHG
LTPQQVVAIASHDGGKQALETVORLLPVLCQAHG
LTPQQVVAIASNNGGKQALETVQALLPVLCQAHG
LTPQQVVAIASNKGKQALETVQALLPVLCQAHG
LTPQQVVAIASNNGGKQALETVORLLPVLCQAHG
LTPQQVVAIASNIGGKQALETVORLLPVLCQAHG
LTPQQVVAIASNNGGKQALETVORLLPVLCQAHG
LTPQQVVAIASHDGGKQALETVORLLPVLCQAHG
LTPQQVVAIASNNGGKQALETVORLLPVLCQAHG
LTPQQVVAIASNNGGKQALETVORLLPVLCQAHG
LTPQQVVAIASNKGKQALETVORLLPVLCQAHG
LTPQQVVAIASNNGGKQALETVQALLPVLCQAHG
LTPQQVVAIASNNGGRPALESIVAQLSRPDPALAAALNDHLVALACLGRPAMDAVKKGLPHAPELIRRVNRRPDPT
GHHHHHH*KL

C) Construct sequences for eukaryotic expression for reporter assays

HAtag: YPYDVPDYA
NLS: PKKKRKV
XhoI: CTCGAG
StuI: AGGCCT
AatII: GACGTC
AgeI: ACCGGT
VP64: DALDDFDLMDLDALDDFDLMDLDALDDFDLMDLDALDDFDLMDL
PstI: CTGCAG

Construct Schema:

HAtag-NLS-XhoI-StuI-TALE_repeats-AatII-AgeI-VP64-Stop-PstI


I-NGp₁₁₁₋₄₂ in pPGK-VP64

ATGTACCCATACGATGTCCAGACTACGCGAATTCCCCGGGGATCCCAGGCATGGGGCCCAAAAAGAAACGCAAAGT
TGGGCGCCTCGAGATGGATCCCTCCGACGCTTCGCCGGCCGCGCAGGTGGATCTACGCACGCTCGGCTACAGTCAGC
AGCAGCAAGAGAAGATCAAACCGAAGGTGCGTTTCGACAGTGGCGCAGCACCACGAGGCACTGGTGGGCCATGGGTTT
ACACACGCGCACATCGTTGCGCTCAGCCAACACCCGGCAGCGTTAGGGACCGTGCCTGTCACGTATCAGCACATAAT
CACGGCGTTGCCAGAGGCGACACACGAAGACATCGTTGGCGTCGGCAAACAGTGGTCCGGCGCACGCGCCCTGGAGG
CCTTGCTCACGGTGGCGGGAGAGTTGAGAGGTCCACCGTTACAGTTGGACACAGGCCAACTTCTCAAGATTGCAAAA
CGTGGCGGCGTGACCCAGTGGAGGCAAGTGCATGCATGGCGCAATGCACTGACGGGTGCCCCCTGAACCTTACGCC
GCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGCTTCCGGTGC
TGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAG
ACGGTGCAGCGATTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAA
TGGCGGTGGCAAGCAGGCGCTGGAGACTGTCCAGCGGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGG
AGCAGGTGGTGGCCATCGCCAGCCACGACGGTGGCAAGCAGGCGCTTGGAGACGGTGCAGCGGCTGTTGCCGGTGTGT
TGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCTCTGGAGAC
GGTGCAGCGGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATA
AGGGGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGCAG
CAGGTGGTGGCCATCGCCAGCAATGGCGGGCGCAAGCAGGCGCTGGAGACGGTGCAGGCGCTGTTGCCGGTGTGTG
CCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCAAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGG
TGCAGGCGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCAATCGCCAGCAATGGC
GGTGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGCAACA
GGTGTGAGCCATCGCCAGCAATATTGGTGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGTGTGTGCC
AGGCCCATGGCCTGACACCCAGCAGGTGGTAGCGATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACGGT
CAGCGGCTGCTTCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGCAGCAGGTGGTGGCCATCGCCAGCAATGGCGG
TGGCAAGCAGGCGCTGGAGACGGTGCAGCGATTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGG
TGGTGGCCATCGCCAGCAATGGCGGTGGCAAGCAGGCGCTGGAGACTGTCCAGCGGCTGTTGCCGGTGTGTGCCAG
GCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATAAGGGTGGCAAGCAGGCGCTTGGAGACGGTGC
GCGGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGTGGTGGCCATCGCCAGCAATGGCGGT
GCAAGCAGGCTCTGGAGACGGTGCAGCGGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACCCCGGAGCAGGT
GTGGCCATCGCCAGCCACGACGGGGCAAGCAGGCGCTGGAGACGGTGCAGCGGCTGTTGCCGGTGTGTGCCAGGC
CCATGGCCTGACCCCGCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGGCGCAAGCAGGCGCTGGAGACGGTGCAGG
CGCTGTTGCCGGTGTGTGCCAGGCCCATGGCCTGACACCCAGCAGGTGGTGGCCATCGCCAGCAATGGCGGGCGG
AGGCCGGCGCTGGAGACGATTGTTGCCAGTTATCTCGCCCTGATCCGGCGTTGGCCGCGTTGACCAACGACCACCT
CGTCGCCTTGGCCTGCCTCGGCGGACGTCCTGCCATGGATGCAGTGAAAAAGGGACTGCCGCACGCGCCGGAATTGA
TCAGAAGATCAATCGCCGTCGGATCCTACCGGTGCGGCCGCCGACGCTTTGGATGACTTTGATTTGGACATGCTG
GATGCTCTAGACTTTCGACCTGGATATGCTGGACGCACTTGGACGACTTTGACCTCGACATGCTAGACGCTCTGGA
CGACTTCGATCTAGACATGCTCTAAGTCGACCTGCAG

MPYDVPDYANSPGIPGMG**PKKKRKV**GRLEMDPSDASPAAQVDLRTLGYSSQQQEKIKPK
VRSTVAQHHEALVGHGFTHAHIVALSQHPAALGTVAVTYQHIITALPEATHEDIVGVGKQ
WSGARALEALLTVAGELRGPPLQ
LDTGQLLKIARKGGVTAVEAVHAWRNALTGAPLN
LTPQQVVAIASNGGKQALETVQRLLPVLCQAHG


LTPEQVVAIASNIGGKQALETVORLLPVLCQAHG
LTPEQVVAIASNNGGKQALETVORLLPVLCQAHG
LTPEQVVAIASHDGGKQALETVORLLPVLCQAHG
LTPEQVVAIASNNGGKQALETVORLLPVLCQAHG
LTPEQVVAIASNKGGKQALETVORLLPVLCQAHG
LTPQQVVAIASNNGGKQALETVQALLPVLCQAHG
LTPEQVVAIASNNGGKQALETVQALLPVLCQAHG
LTPEQVVAIASNNGGKQALETVORLLPVLCQAHG
LTPQQVVAIASNIGGKQALETVORLLPVLCQAHG
LTPQQVVAIASNNGGKQALETVORLLPVLCQAHG
LTPQQVVAIASNNGGKQALETVORLLPVLCQAHG
LTPEQVVAIASNNGGKQALETVORLLPVLCQAHG
LTPEQVVAIASNKGGKQALETVORLLPVLCQAHG
LTPEQVVAIASNNGGKQALETVORLLPVLCQAHG
LTPEQVVAIASHDGGKQALETVORLLPVLCQAHG
LTPQQVVAIASNNGGKQALETVQALLPVLCQAHGLTPQQVVAIASNNGGRPALESIVAQ
LSRPDPALAALTNDHLVALACLGGRPAMDAVKKGLPHAPELIRRVRPDPTGAAADALD
DFDLMDALDDFDLMDALDDFDLMDALDDFDLMDL*VDLQ

Figure S2: Coomassie-stained protein gel of representative dTALEs.




A) Coomassie-stained SDS PAGE gel shows purified **AvrBs3**₂₅₄₋₁₈₀ after treatment with various concentrations of Factor Xa protease. B) Purified dTALE₁₁₁₋₄₂ proteins run at the expected 100 kilodalton size. Proteins shown are diluted 1:5 from stock. Typical protein yields were between 10 and 30 μ M.

Figure S3. Representative EMSA data.



Sample data showing the EMSA dynamic range of 10^4 . The TALEs used are shown and unless stated, the cognate DNA targets are used. The shifted TALE-DNA band is indicated with an arrow while the unshifted DNA is indicated with a “*”. The bottom panel shows representative data for a mixed site target used in polarity experiments. The sharpness of the transition (apparent $nH = 3-4$) is consistent over 4 logs of protein concentration, and therefore is not due to lack of equilibration or protein concentration-dependent aggregation. We do not know its origin.

Figure S4: Correlation of affinity with reporter gene activation.



The relationship between apparent K_D and fold activation of the reporter gene was not linear.

The best fit model of these data was a log-log relationship. The correlation of $\log_2(\text{Fold}$

Activation) versus $\log_{10}(\text{Apparent } K_D \text{ (pM)})$ had an $R^2 = 0.68$ and a $P = 0.0002$. Host context is

indicated by color, guest RVD by letter; G, NG; N, NN; D, HD; I, NI; K, NK.

Table S1: Primers used to create N- and C-terminal truncations.

EcoRI: GAATTC

5'SfiI: GGCCGCTAAGGCC

3'SfiI: GGCCAAGCTGGCC

XhoI: CTCGAG

BamHI: GGATCC

SmaI: CCCGGG

AgeI: ACCGGT

>PthXoI_5'111-f

5'-

AATAGGAGGTGCACCGAATTCGTGGCCGCTAAGGCCCTCGAGATGGATCC

>PthXoI_5'94-f

5'-

AATAGGAGGTGCACCGAATTCGTGGCCGCTAAGGCCCTCGAGATGGATCCAGTCAGCAGCAGCAAGAGAAGATCAAA
CC

>PthXoI_5'end-r

5'-CGACGAGGTGGTTCGTTGGTCAACGCCCGGGCTGTAACGGCGGACCTCTCAACTC

>PthXoI_3'end-f

5'-GAGTTGAGAGGTCCGCCGTTACAGCCCGGGCGTTGACCAACGACCACCTCGTCG

>PthXoI_3'42-r

5'-

CAAGAAAGCTGGGTCTGAATTCGGCCAAGCTGGCCTTACCGGTAGGATCCGGACGGCGATTGACTCTTCTGATCAATT
C

Table S2: Primers used in EMSA assays.

Biotinylated forward primer /5Biosg/CCTCTTCGCTATTACGCCAGC
 Reverse primer CACCCTGACTCGAGTACGATCGAACGTTTC

For RVD affinity studies

I-A	CCTCTTCGCTATTACGCCAGC	TAAACAGATAAATAGACAA	GAACGTTTCGATCGTACTCGAGTCAGGGTG
I-G	CCTCTTCGCTATTACGCCAGC	TGAGCGGGTGAGTGGGCGG	GAACGTTTCGATCGTACTCGAGTCAGGGTG
I-C	CCTCTTCGCTATTACGCCAGC	TCACCCGCTCACTCGCCCC	GAACGTTTCGATCGTACTCGAGTCAGGGTG
I-T	CCTCTTCGCTATTACGCCAGC	TTATCTGTTTTATTTGTCTT	GAACGTTTCGATCGTACTCGAGTCAGGGTG
II-A	CCTCTTCGCTATTACGCCAGC	TAAATACAGAAACATAGAA	GAACGTTTCGATCGTACTCGAGTCAGGGTG
II-G	CCTCTTCGCTATTACGCCAGC	TGAGTGCGGGAGCGTGGGG	GAACGTTTCGATCGTACTCGAGTCAGGGTG
II-C	CCTCTTCGCTATTACGCCAGC	TCACTCCCGCACCCCTCGCC	GAACGTTTCGATCGTACTCGAGTCAGGGTG
II-T	CCTCTTCGCTATTACGCCAGC	TTATTTCTGTATCTTTGTT	GAACGTTTCGATCGTACTCGAGTCAGGGTG
III-A	CCTCTTCGCTATTACGCCAGC	TACAAAGACATAGAAATAA	GAACGTTTCGATCGTACTCGAGTCAGGGTG
III-G	CCTCTTCGCTATTACGCCAGC	TGCGAGGGCGTGGGAGTGG	GAACGTTTCGATCGTACTCGAGTCAGGGTG
III-C	CCTCTTCGCTATTACGCCAGC	TCCCACGCCCTCGCACTCC	GAACGTTTCGATCGTACTCGAGTCAGGGTG
III-T	CCTCTTCGCTATTACGCCAGC	TTCTATGTCTTTGTATTTT	GAACGTTTCGATCGTACTCGAGTCAGGGTG

Zif268 CCTCTTCGCTATTACGCCAGC GCGTGGGCGT GAACGTTTCGATCGTACTCGAGTCAGGGTG

For 5'T studies

Bs3	CCTCTTCGCTATTACGCCAGC	TATATAAACCTAACCATCC	GAACGTTTCGATCGTACTCGAGTCAGGGTG
5'A	CCTCTTCGCTATTACGCCAGC	AATATAAACCTAACCATCC	GAACGTTTCGATCGTACTCGAGTCAGGGTG
5'C	CCTCTTCGCTATTACGCCAGC	CATATAAACCTAACCATCC	GAACGTTTCGATCGTACTCGAGTCAGGGTG
5'G	CCTCTTCGCTATTACGCCAGC	GATATAAACCTAACCATCC	GAACGTTTCGATCGTACTCGAGTCAGGGTG

For polarity studies (B = C,G,T; D = A,G,T; H = A,C,T; V = A,C,G)

Bs3 variants

3m3	CCTCTTCGCTATTACGCCAGC	TATATAAACCTAACCAVDD	GAACGTTTCGATCGTACTCGAGTCAGGGTG
3m6	CCTCTTCGCTATTACGCCAGC	TATATAAACCTAADDVDD	GAACGTTTCGATCGTACTCGAGTCAGGGTG
3m9	CCTCTTCGCTATTACGCCAGC	TATATAAACCVBBDDBVDD	GAACGTTTCGATCGTACTCGAGTCAGGGTG
5m3	CCTCTTCGCTATTACGCCAGC	TBVBTAACCTAACCATCC	GAACGTTTCGATCGTACTCGAGTCAGGGTG
5m6	CCTCTTCGCTATTACGCCAGC	TBVBVBACCTAACCATCC	GAACGTTTCGATCGTACTCGAGTCAGGGTG
5m9	CCTCTTCGCTATTACGCCAGC	TBVBVBBDDBTAACCATCC	GAACGTTTCGATCGTACTCGAGTCAGGGTG

III-C variants

3m3	CCTCTTCGCTATTACGCCAGC	TCCCACGCCCTCGCACVDD	GAACGTTTCGATCGTACTCGAGTCAGGGTG
3m6	CCTCTTCGCTATTACGCCAGC	TCCCACGCCCTCGDBDVDD	GAACGTTTCGATCGTACTCGAGTCAGGGTG
3m9	CCTCTTCGCTATTACGCCAGC	TCCCACGCCVVDHDBDVDD	GAACGTTTCGATCGTACTCGAGTCAGGGTG
5m3	CCTCTTCGCTATTACGCCAGC	TDDDACGCCCTCGCACTCC	GAACGTTTCGATCGTACTCGAGTCAGGGTG
5m6	CCTCTTCGCTATTACGCCAGC	TDDDBDHCCCTCGCACTCC	GAACGTTTCGATCGTACTCGAGTCAGGGTG
5m9	CCTCTTCGCTATTACGCCAGC	TDDDBDHDDDTCGCACTCC	GAACGTTTCGATCGTACTCGAGTCAGGGTG

III-T variants

3m3	CCTCTTCGCTATTACGCCAGC	TTCTATGTCTTTGTATVVV	GAACGTTTCGATCGTACTCGAGTCAGGGTG
3m6	CCTCTTCGCTATTACGCCAGC	TTCTATGTCTTTGVBVVVV	GAACGTTTCGATCGTACTCGAGTCAGGGTG
3m9	CCTCTTCGCTATTACGCCAGC	TTCTATGTCTVVHVVBVVVV	GAACGTTTCGATCGTACTCGAGTCAGGGTG
5m3	CCTCTTCGCTATTACGCCAGC	TVDVATGTCCTTTGTATTTT	GAACGTTTCGATCGTACTCGAGTCAGGGTG
5m6	CCTCTTCGCTATTACGCCAGC	TVDVBVHTCTTTGTATTTT	GAACGTTTCGATCGTACTCGAGTCAGGGTG
5m9	CCTCTTCGCTATTACGCCAGC	TVDVBVHVDVTTGTATTTT	GAACGTTTCGATCGTACTCGAGTCAGGGTG

Table S3: Primers for construction of ATF reporter plasmids.

XhoI: **CTCGAG**
NotI: **GCGGCCGC**

For RVD studies

>pGL3-control-Not-F
5'- GAGGAG**GCGGCCGC**CAATAAAATATCTTTATTTTC

>PGL3-I-A-R
5'- CTCCTC**CTCGAG**TTGTCTATTTATCTGTTTACCCGGGCTAGCACGCGTAAGAGCTC -3'

>PGL3-I-G-R
5'- CTCCTC**CTCGAG**CCGCCACTCACCCGCTCACCCGGGCTAGCACGCGTAAGAGCTC -3'

>PGL3-I-C-R
5'- CTCCTC**CTCGAG**GGGGCGAGTGAGCGGGTGACCCGGGCTAGCACGCGTAAGAGCTC -3'

>PGL3-I-T-R
5'- CTCCTC**CTCGAGA**AAGACAAATAAACAGATAACCCGGGCTAGCACGCGTAAGAGCTC -3'

>PGL3-II-A-R
5'- CTCCTC**CTCGAG**TTCTATGTTTCTGTATTTACCCGGGCTAGCACGCGTAAGAGCTC -3'

>PGL3-II-G-R
5'- CTCCTC**CTCGAG**CCCCACGCTCCCGCACTCACCCGGGCTAGCACGCGTAAGAGCTC -3'

>PGL3-II-C-R
5'- CTCCTC**CTCGAG**GGCGAGGGTGCGGGAGTGACCCGGGCTAGCACGCGTAAGAGCTC -3'

>PGL3-II-T-R
5'- CTCCTC**CTCGAGA**ACAAAGATACAGAAATAACCCGGGCTAGCACGCGTAAGAGCTC -3'

>PGL3-III-A-R
5'- CTCCTC**CTCGAG**TTATTTCTATGTCTTTGTACCCGGGCTAGCACGCGTAAGAGCTC -3'

>PGL3-III-G-R
5'- CTCCTC**CTCGAG**CCACTCCCACGCCCTCGCACCCGGGCTAGCACGCGTAAGAGCTC -3'

>PGL3-III-C-R
5'- CTCCTC**CTCGAG**GGAGTGCGAGGGCGTGGGACCCGGGCTAGCACGCGTAAGAGCTC -3'

>PGL3-III-T-R
5'- CTCCTC**CTCGAG**AAAATACAAAGACATAGAACCCGGGCTAGCACGCGTAAGAGCTC -3'

For AvrBs3 variant studies

>PGL3-Bs3-wt-R
5'- CTCCTC**CTCGAG**GGATGGTTAGGTTTATATAACCCGGGCTAGCACGCGTAAGAGCTC -3'

>pGL3-Bs3-UPA-R
5'- CTCCTC**CTCGAG**AGAGGGTTAGGTTTATATAACCCGGGCTAGCACGCGTAAGAGCTC -3'

For AvrBs3 5'T studies

>PGL3-Bs3-5A-R
5'- CTCCTCCTCGAGGGATGGTTAGGTTTATATTCCCGGGCTAGCACGCGTAAGAGCTC -3'
>PGL3-Bs3-5C-R
5'- CTCCTCCTCGAGGGATGGTTAGGTTTATATGCCCGGGCTAGCACGCGTAAGAGCTC -3'
>PGL3-Bs3-5G-R
5'- CTCCTCCTCGAGGGATGGTTAGGTTTATATCCCGGGCTAGCACGCGTAAGAGCTC -3'

For polarity studies

>PGL3-Bs3-3m3-R
5'- CTCCTCCTCGAGCCCTGGTTAGGTTTATATACCCGGGCTAGCACGCGTAAGAGCTC -3'
>PGL3-Bs3-3m6-R
5'- CTCCTCCTCGAGCCCCCTTAGGTTTATATACCCGGGCTAGCACGCGTAAGAGCTC -3'
>PGL3-Bs3-3m9-R
5'- CTCCTCCTCGAGCCCCCAACGGTTTATATACCCGGGCTAGCACGCGTAAGAGCTC -3'
>PGL3-Bs3-5m3-R
5'- CTCCTCCTCGAGGGATGGTTAGGTTTAACCACCCGGGCTAGCACGCGTAAGAGCTC -3'
>PGL3-Bs3-5m6-R
5'- CTCCTCCTCGAGGGATGGTTAGGTAACACCACCCGGGCTAGCACGCGTAAGAGCTC -3'
>PGL3-Bs3-5m9-R
5'- CTCCTCCTCGAGGGATGGTTACCAAACACCACCCGGGCTAGCACGCGTAAGAGCTC -3'
>PGL3-III-T-3m3-R
5'- CTCCTCCTCGAGCCCATACAAAGACATAGAACCCGGGCTAGCACGCGTAAGAGCTC -3'
>PGL3-III-T-3m6-R
5'- CTCCTCCTCGAGCCCCACCAAAGACATAGAACCCGGGCTAGCACGCGTAAGAGCTC -3'
>PGL3-III-T-3m9-R
5'- CTCCTCCTCGAGCCCCACGCCAGACATAGAACCCGGGCTAGCACGCGTAAGAGCTC -3'
>PGL3-III-T-5m3-R
5'- CTCCTCCTCGAGAAAATACAAAGACATCCCACCCGGGCTAGCACGCGTAAGAGCTC -3'
>PGL3-III-T-5m6-R
5'- CTCCTCCTCGAGAAAATACAAAGAGCACCCACCCGGGCTAGCACGCGTAAGAGCTC -3'
>PGL3-III-T-5m9-R
5'- CTCCTCCTCGAGAAAATACAACCCGCACCCACCCGGGCTAGCACGCGTAAGAGCTC -3'

Alignment

>PGL3-Bs3-UPA-R	TATATAAACCTAACCTCT
>PGL3-Bs3-wt-R	TATATAAACCTAACCATCC
>PGL3-Bs3-5A-R	<u>A</u> AATATAAACCTAACCATCC
>PGL3-Bs3-5C-R	<u>C</u> ATATAAACCTAACCATCC

>PGL3- <i>Bs3</i> -5G-R	<u>GATATAAACCTAACCATCC</u>
>PGL3-I-A-R	TAAACAGATAAATAGACAA
>PGL3-I-G-R	TGAGCGGGTGAGTGGGCGG
>PGL3-I-C-R	TCACCCGCTCACTCGCCCC
>PGL3-I-T-R	TTATCTGTTTATTTGTCTT
>PGL3-II-A-R	TAAATACAGAAACATAGAA
>PGL3-II-G-R	TGAGTGCGGGAGCGTGGGG
>PGL3-II-C-R	TCACTCCCGCACCCCTCGCC
>PGL3-II-T-R	TTATTTCTGTATCTTTGTT
>PGL3-III-A-R	TACAAAGACATAGAAATAA
>PGL3-III-G-R	TGCGAGGGCGTGGGAGTGG
>PGL3-III-C-R	TCCCACGCCCTCGCACTCC
>PGL3-III-T-R	TTCTATGTCTTTGTATTTT
>PGL3- <i>Bs3</i> -wt-R	TATATAAACCTAACCATCC
>PGL3- <i>Bs3</i> -3m3-R	TATATAAACCTAACCAGGG
>PGL3- <i>Bs3</i> -3m6-R	TATATAAACCTAAGGGGGG
>PGL3- <i>Bs3</i> -3m9-R	TATATAAACCGTTGGGGGG
>PGL3- <i>Bs3</i> -5m3-R	TGGTTAAACCTAACCATCC
>PGL3- <i>Bs3</i> -5m6-R	TGGTGTTACCTAACCATCC
>PGL3- <i>Bs3</i> -5m9-R	TGGTGTTTGGTAACCATCC
>PGL3-III-T-wt-R	TTCTATGTCTTTGTATTTT
>PGL3-III-T-3m3-R	TTCTATGTCTTTGTATGGG
>PGL3-III-T-3m6-R	TTCTATGTCTTTGGTGGGG
>PGL3-III-T-3m9-R	TTCTATGTCTGGCGTGGGG
>PGL3-III-T-5m3-R	TGGGATGTCTTTGTATTTT
>PGL3-III-T-5m6-R	TGGGTGCTCTTTGTATTTT
>PGL3-III-T-5m9-R	TGGGTGCGGGTTGTATTTT

Table S4: EMSA and ATF data for G/A specificity of the NN RVD.

dTALE	Target Site	Apparent K_D (nM)	Fold increase in apparent K_D over G guest	Fold Activation	Fold decrease in activation over G guest
I-NNp	I-G	1.3 ± 0.3		5.1 ± 0.4	
I-NNp	I-A	64 ± 5	49	0.86 ± 0.17	6
II-NNp	II-G	1.3 ± 0.3		19 ± 2	
II-NNp	II-A	53 ± 11	41	2.4 ± 0.1	8
III-NNp	III-G	0.6 ± 0.2		6.5 ± 0.9	
III-NNp	III-A	10 ± 4	17	0.53 ± 0.03	12

Table S5: EMSA and ATF data probing the requirement of a 5'T.

Protein	5' Base	Apparent K_D (nM)	Fold increase in apparent K_D compared to 5' T	% affinity of 5' T control**	Fold Activation	Fold decrease in activation compared to 5' T
AvrBs3 ₁₁₁₋₄₂	T	$1.1 \pm 0.04^*$		100	3.9 ± 0.6	
AvrBs3 ₁₁₁₋₄₂	A	16 ± 4.8	15	7.5 ± 2.6	1.1 ± 0.1	3.5
AvrBs3 ₁₁₁₋₄₂	C	22 ± 0.7	20	5.0 ± 0.1	1.2 ± 0.2	3.3
AvrBs3 ₁₁₁₋₄₂	G	21 ± 6.4	19	5.4 ± 1.3	1.0 ± 0.2	3.9
dAvrBs3 ₁₁₁₋₄₂	T	$2.6 \pm 1.5^*$		100	4.7 ± 0.3	
dAvrBs3 ₁₁₁₋₄₂	A	4.3 ± 0.3	1.7	36 ± 3	3.5 ± 0.3	1.3
dAvrBs3 ₁₁₁₋₄₂	C	9.6 ± 3.7	3.7	40 ± 13	3.4 ± 0.3	1.4
dAvrBs3 ₁₁₁₋₄₂	G	8.4 ± 0.4	3.2	43 ± 2	3.1 ± 0.5	1.5

* These values of AvrBs3₁₁₁₋₄₂ and dAvrBs3₁₁₁₋₄₂ binding to the *Bs3* targets represent the average of two independent EMSA experiments performed on the same days as other individual determinations in the table. The values differ from that in Table 1, but were included in the computation of the Table 1 value.

** Percentage affinities of 5' A, C and G were calculated using the values for AvrBs3₁₁₁₋₄₂ or dAvrBs3₁₁₁₋₄₂ binding to *Bs3* (5' T) targets, determined on the same day, as a reference.

Table S6: EMSA and ATF data for polarity effects.

Protein	Target	Apparent K_D (nM)	% wild type K_A	Fold Activation
III-HDp	wt	0.6 ± 0.1	100	n.d.
III-HDp	5m3	35 ± 3.7	1.7 ± 0.3	n.d.
III-HDp	5m6	530 ± 134	0.12 ± 0.02	n.d.
III-HDp	5m9	>1650	<0.04	n.d.
III-HDp	3m3	1.7 ± 1.0	44 ± 21	n.d.
III-HDp	3m6	39 ± 28	2.4 ± 1.9	n.d.
III-HDp	3m9	68 ± 23	0.91 ± 0.16	n.d.
III-NGp	wt	0.3 ± 0.1	100	4.3 ± 0.45
III-NGp	5m3	4.2 ± 0.7	6.5 ± 2.9	0.35 ± 0.09
III-NGp	5m6	100 ± 10	0.27 ± 0.13	0.18 ± 0.02
III-NGp	5m9	320 ± 76	0.08 ± 0.03	0.14 ± 0.04
III-NGp	3m3	0.3 ± 0.1	95 ± 8.8	3.1 ± 1.4
III-NGp	3m6	0.5 ± 0.2	49 ± 11	5.3 ± 1.4
III-NGp	3m9	2.5 ± 1.1	12 ± 6	1.6 ± 0.33
AvrBs3 ₁₁₁₋₄₂	wt	5.4 ± 2.6	100	3.9 ± 0.32
AvrBs3 ₁₁₁₋₄₂	5m3	115 ± 11	3.4 ± 1.2	1.2 ± 0.07
AvrBs3 ₁₁₁₋₄₂	5m6	>1500	<0.25	1.1 ± 0.15
AvrBs3 ₁₁₁₋₄₂	5m9	>1500	<0.25	1.2 ± 0.17
AvrBs3 ₁₁₁₋₄₂	3m3	140 ± 78	4.4 ± 2.1	1.3 ± 0.03
AvrBs3 ₁₁₁₋₄₂	3m6	490 ± 48	0.77 ± 0.18	1.0 ± 0.22
AvrBs3 ₁₁₁₋₄₂	3m9	970 ± 64	0.58 ± 0.29	1.1 ± 0.08
dAvrBs3 ₁₁₁₋₄₂	wt	3.2 ± 0.7	100	4.7 ± 0.35
dAvrBs3 ₁₁₁₋₄₂	5m3	1100 ± 85	0.29 ± 0.04	0.52 ± 0.05
dAvrBs3 ₁₁₁₋₄₂	5m6	>1500	<0.22	0.55 ± 0.04
dAvrBs3 ₁₁₁₋₄₂	5m9	>1500	<0.22	0.60 ± 0.04
dAvrBs3 ₁₁₁₋₄₂	3m3	46 ± 12	7.4 ± 2.7	1.4 ± 0.06
dAvrBs3 ₁₁₁₋₄₂	3m6	120 ± 23	2.7 ± 0.59	1.2 ± 0.15
dAvrBs3 ₁₁₁₋₄₂	3m9	93 ± 5.3	3.5 ± 0.66	1.0 ± 0.08
n.d., not done				

References

1. Mussolino, C. and Cathomen, T. (2012) TALE nucleases: tailored genome engineering made easy. *Curr Opin Biotechnol*.
2. Miller, J.C., Tan, S., Qiao, G., Barlow, K.A., Wang, J., Xia, D.F., Meng, X., Paschon, D.E., Leung, E., Hinkley, S.J. *et al.* (2011) A TALE nuclease architecture for efficient genome editing. *Nat Biotechnol*, **29**, 143-148.
3. Sun, N., Liang, J., Abil, Z. and Zhao, H. (2012) Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease. *Mol Biosyst*, **8**, 1255-1263.
4. Mak, A.N., Bradley, P., Cernadas, R.A., Bogdanove, A.J. and Stoddard, B.L. (2012) The crystal structure of TAL effector PthXo1 bound to its DNA target. *Science*, **335**, 716-719.
5. Zhang, F., Cong, L., Lodato, S., Kosuri, S., Church, G.M. and Arlotta, P. (2011) Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. *Nat Biotechnol*, **29**, 149-153.
6. Deng, D., Yan, C., Pan, X., Mahfouz, M., Wang, J., Zhu, J.K., Shi, Y. and Yan, N. (2012) Structural basis for sequence-specific recognition of DNA by TAL effectors. *Science*, **335**, 720-723.